In the fourth quarter, the company’s revenue grew 10 percent to $6 billion. The sales growth was attributed to Bristol’s top-selling products, including its lung cancer drug Opdivo and blood thinner Eliquis, which saw sales rise 33 percent and 25 percent, respectively.
For fiscal year 2018, Bristol Myers reported a profit of $4.95 billion and sales of $22.6 billion.
The results exceeded Wall Street expectations.
More articles on pharmacy:
Bayer to shut down Pennsylvania plant, eliminate 600 jobs
New drug shortages rose 27% in 2018
FDA moves to fast-track OTC naloxone
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.